These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27528362)

  • 21. Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma.
    Verma J; Lal S; Van Noorden CJ
    Int J Nanomedicine; 2014; 9():2863-77. PubMed ID: 24959075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
    Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Glioblastoma, Present and Future.
    Oberheim Bush NA; Hervey-Jumper SL; Berger MS
    World Neurosurg; 2019 Nov; 131():328-338. PubMed ID: 31658576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma.
    Voth BL; Pelargos PE; Barnette NE; Bhatt NS; Chen CHJ; Lagman C; Chung LK; Nguyen T; Sheppard JP; Romiyo P; Mareninov S; Kickhoefer VA; Yong WH; Rome LH; Yang I
    J Neurooncol; 2020 May; 147(3):599-605. PubMed ID: 32274629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
    Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
    Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
    Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
    Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temozolomide nanoparticles for targeted glioblastoma therapy.
    Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanotechnology applications for glioblastoma.
    Nduom EK; Bouras A; Kaluzova M; Hadjipanayis CG
    Neurosurg Clin N Am; 2012 Jul; 23(3):439-49. PubMed ID: 22748656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
    Juratli TA; Schackert G; Krex D
    Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
    Yang J; Shi Z; Liu R; Wu Y; Zhang X
    Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma.
    Šamec N; Zottel A; Videtič Paska A; Jovčevska I
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats.
    Zhang C; Nance EA; Mastorakos P; Chisholm J; Berry S; Eberhart C; Tyler B; Brem H; Suk JS; Hanes J
    J Control Release; 2017 Oct; 263():112-119. PubMed ID: 28279797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy.
    Moosavian SA; Bianconi V; Pirro M; Sahebkar A
    Semin Cancer Biol; 2021 Feb; 69():337-348. PubMed ID: 31585213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme.
    Pottoo FH; Javed MN; Rahman JU; Abu-Izneid T; Khan FA
    Semin Cancer Biol; 2021 Feb; 69():391-398. PubMed ID: 32302695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New frontiers for astrocytic tumours.
    Nano R; Lascialfari A; Corti M; Paolini A; Pasi F; Corbella F; DI Liberto R
    Anticancer Res; 2012 Jul; 32(7):2755-8. PubMed ID: 22753735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extracellular Vesicles in Glioma: From Diagnosis to Therapy.
    Basu B; Ghosh MK
    Bioessays; 2019 Jul; 41(7):e1800245. PubMed ID: 31188499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.